Risk Of Developing Liver Cancer After HCV Treatment

Wednesday, September 11, 2013

Investment Commentary; Sofosbuvir- Gilead's Lurking Hepatitis C Megablockbuster Drug

Investment Commentary

In this video, health care analysts David Williamson and Max Macaluso drill down on Gilead's strong drug development pipeline.




Source - A site for investors: Motley Fool

No comments:

Post a Comment